Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tebentafusp - Immunocore

Next Previous
Drug Profile

Tebentafusp - Immunocore

Alternative Names: IMC-gp100; ImmTAC-gp100; KIMMTRAK; Monoclonal T cell receptor anti-CD3 scFv fusion protein (IMCgp100); Tebentafusp-tebn

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunocore
  • Developer Immunocore; Natera; University of Oxford
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Uveal melanoma
  • Phase II/III Malignant melanoma

Most Recent Events

  • 11 Mar 2024 Launched for Uveal melanoma (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia (IV) (Prior to February 2024)
  • 28 Feb 2024 Launched for Uveal melanoma (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Canada (IV) (Prior to February 2024)
  • 07 Nov 2023 Immunocore enters into a clinical trial collaboration agreement with The European Organisation for Research and Treatment of Cancer (EORTC) to investigate tebentafusp adjuvant treatment for uveal melanoma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top